Chimeric antigen receptor (CAR) modified T Cells in acute myeloid leukemia: limitations and expectations
Frontiers in Cell and Developmental Biology · 17.04.2024 · 12
DOI: 10.3389/fcell.2024.1376554 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 17.04.2024. Verfasst von Beatriz Guijarro-Albaladejo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Servicio de Hematología, Hospital Univ…. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with a poor prognosis despite the advent of novel therapies. Consequently, a major need exists for new therapeutic options, particularly for patients with relapsed/refractory (R/R) AML. In recent years, it has been possible to individualize the treatment of a subgroup of patients, particularly with the emergence of multiple targeted therapies. Nonetheless, a considerable number of patients remain without therapeutic options, and overall prognosis remains poor because of a high rate of disease relapse. In this sense, cellular therapies, especially chimeric antigen receptor (CAR)-T cell therapy, have dramatically shifted the therapeutic options for other hematologic malignancies, such as diffuse large B cell lymphoma and acute lymphoblastic leukemia. In contrast, effectively treating AML with CAR-based immunotherapy poses major biological and clinical challenges, most of them derived from the unmet need to identify target antigens with expression restricted to the AML blast without compromising the viability of the normal hematopoietic stem cell counterpart. Although those limitations have hampered CAR-T cell therapy translation to the clinic, there are several clinical trials where target antigens, such as CD123, CLL-1 or CD33 are being used to treat AML patients showing promising results. Moreover, there are continuing efforts to enhance the specificity and efficacy of CAR-T cell therapy in AML. These endeavors encompass the exploration of novel avenues, including the development of dual CAR-T cells and next-generation CAR-T cells, as well as the utilization of gene editing tools to mitigate off-tumor toxicities. In this review, we will summarize the ongoing clinical studies and the early clinical results reported with CAR-T cells in AML, as well as highlight CAR-T cell limitations and the most recent approaches to overcome these barriers. We will also discuss how and when CAR-T cells should be used in the context of AML.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Servicio de Hematología, Hospital Universitario Virgen del Rocío, Seville, Spain.
- Unidad de Gestión Clínica de Hematología, Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.
Zitieren
APA
Guijarro-Albaladejo, B., Marrero-Cepeda, C., Rodríguez-Arbolí, E., Sierro-Martínez, B., Pérez-Simón, J. A., & García-Guerrero, E. (2024). Chimeric antigen receptor (CAR) modified T Cells in acute myeloid leukemia: limitations and expectations. Frontiers in Cell and Developmental Biology, 12. https://doi.org/10.3389/fcell.2024.1376554
Vancouver
Guijarro-Albaladejo B, Marrero-Cepeda C, Rodríguez-Arbolí E, Sierro-Martínez B, Pérez-Simón JA, García-Guerrero E. Chimeric antigen receptor (CAR) modified T Cells in acute myeloid leukemia: limitations and expectations. Frontiers in Cell and Developmental Biology. 2024;12. doi:10.3389/fcell.2024.1376554
BibTeX
@article{GuijarroAlbaladejo2024,
author = {Guijarro-Albaladejo, Beatriz and Marrero-Cepeda, Cristina and Rodríguez-Arbolí, Eduardo and Sierro-Martínez, Belén and Pérez-Simón, José Antonio and García-Guerrero, Estefanía},
title = {Chimeric antigen receptor (CAR) modified T Cells in acute myeloid leukemia: limitations and expectations},
journal = {Frontiers in Cell and Developmental Biology},
year = {2024},
volume = {12},
doi = {10.3389/fcell.2024.1376554}
}
EUVIMED